- The transaction includes approximately €176 million of cash consideration at closing and up to €35 million in milestone payments; Enovis expects to close by year-end 2026 pending regulatory approvals.
- Enovis plans to launch a next-generation robotic platform for total knee procedures within two years, with an initial commercial contribution beginning in 2028 and a shoulder application to follow.
- The deal adds more than 50 robotics engineers and creates a Grenoble, France, center of excellence, while Enovis expects roughly 100 basis points of adjusted EBITDA margin pressure in 2027 before returning to year-over-year margin improvement in 2028.
Quotes
“This acquisition is a significant milestone and reflects our disciplined approach to bringing externally developed innovation into Enovis.”
“The eCential transaction is more than just a robot.”
“Our strategy at eCential Robotics has always been to offer surgeons easy-to-use, cutting-edge technology to improve surgical workflows, and ultimately, enable better patient outcomes.”